The Diabetic Neuropathies: Practical and Rational Therapy

J. Robinson Singleton, M.D.1, 2 A. Gordon Smith, M.D.1, 3

1 University of Utah School of Medicine, Salt Lake City, Utah
2 Department of Neurology
3 Department of Neurology and Pathology


Abstract

Diabetes is associated with a variety of chronic and acute neuropathies. In this article, the authors summarize the clinical features of the most common diabetic neuropathies, focusing on those for which therapy is available or under active investigation. Distal symmetric polyneuropathy (DSP) is the most common form. Potential treatments for DSP are discussed in four broad themes: (1) medication and lifestyle therapy to improve hyperglycemia, insulin resistance, and attendant features of metabolic syndrome, including obesity and dyslipidemia; (2) pharmacologic therapy to alter neuropathy natural history aimed at rational targets from known pathophysiology; (3) symptomatic relief of neuropathic pain; and (4) treatment to prevent complications of neuropathy, including stasis ulcers and falls. The approach to the most common acute diabetic neuropathies is also reviewed.

Keywords
► diabetes
► peripheral neuropathy
► diabetic amyotrophy

Clinical Features of Diabetic Neuropathy

Distal symmetric polyneuropathy (DSP) is the most common neuropathic complication of diabetes; 50% or more of patients develop DSP, and up to 20% have clinical features of neuropathy at the time of diabetes diagnosis. Distal symmetric polyneuropathy causes “positive” and “negative” sensory symptoms in a length-dependent pattern, affecting the toes and distal foot, spreading over time to the ankle and proximally. Patients may describe numbness, or may be unaware of their sensory loss until demonstrated on exam. Positive symptoms consist of abnormal spontaneous “paresthesias” such as pricking, tingling, or burning; “alldynia,” perception of nonpainful stimuli as painful; or “hyperalgesia,” inappropriate exaggeration of painful sensation. Two in five diabetic patients with DSP experience neuropathic pain, which is often the principal source of disability. The pain is often described as “deep aching,” “burning,” “electric,” “tingling,” or “sharp.” Although pain frequently limits activities and is worse with walking, it is most severe at nighttime and sometimes inhibits sleep. Pain is typically moderate to severe. The average pain intensity in a survey of 105 painful DSP patients was 5.8/10.1

Distal symmetric polyneuropathy is a major cause of disability and reduced quality of life. Those with severe neuropathy may suffer painless injury. With more advanced disease, motor denervation can result in foot intrinsic muscle atrophy, exaggerated foot arch, and hammer toes. Foot and ankle instability due to weakness and reduced proprioception leads to falls, sprains, foot bone fractures, and other orthopedic injuries. Loss of protective sensation combined with altered sweating and poor wound healing predispose patients with DSP to foot ulcers, Charcot foot abnormalities, and amputation.

Evaluation should proceed from focused questions about pain, paresthesias, sensory loss, and weakness to an exam tailored to detection of length-dependent nerve injury. Strength is often normal, but there may be atrophy of foot muscles. Atrophy of hand muscles is more often due to focal compressive mononeuropathies of ulnar or median nerves. Deep tendon reflexes are characteristically reduced or absent at the ankles and well-preserved distal reflexes in the face of other neuropathic features should prompt consideration of a structural myelopathy or a dorsal column neuropathy, such as B12 deficiency. Sensory testing should evaluate the severity (absence vs reduced) and distribution of sensory loss to modalities associated with small unmyelinated (pain and autonomic) and large myelinated (proprioceptive, touch, vibratory, temperature).
Focal, Acute, and Regional Forms of Diabetic Peripheral Nerve Injury

Compressive mononeuropathies, especially ulnar, median, and peroneal, are more common in diabetes. Bilateral and nondominant median mononeuropathy at the wrist are more common in diabetes, although obesity, rather than diabetes, may be the primary driver of increased carpal tunnel syndrome risk. Hand numbness suggests bilateral median mononeuropathies at the wrist (carpal tunnel syndrome) and/or ulnar mononeuropathy at the elbow (cubital tunnel syndrome) in preference to advanced DSP. Nerve conduction studies should be performed to confirm compressive ulnar or median mononeuropathies, and to screen for associated axonal injury. Those with pure demyelinating defects in peripheral sweat generation in response to axonal injury. Those with pure demyelinating injury may be the primary driver of increased carpal tunnel syndrome risk. Hand numbness suggests bilateral median mononeuropathies at the wrist (carpal tunnel syndrome) and/or ulnar mononeuropathy at the elbow (cubital tunnel syndrome) in preference to advanced DSP. Nerve conduction studies should be performed to confirm compressive ulnar or median mononeuropathies, and to screen for associated axonal injury. Those with pure demyelinating injuries have noted higher obesity rates in patients with idiopathic neuropathy, both with and without abnormal glucose metabolism. Several metabolic syndrome features have been linked to neuropathy, particularly obesity and dyslipidemia, independent of hyperglycemia. The largest studies have examined metabolic syndrome contribution to neuropathy risk in patients with known diabetes. The EuroDiab study found DSP in 28% of type 1 diabetic patients. It was noted that many patients with good glucose control (hemoglobin A1c < 7%) had DSP, suggesting other risk factors were important. Among patients who did not have neuropathy at baseline, 23.5% developed neuropathy after an average follow up of 7.3 years. Hypertension, serum lipids and triglycerides, body mass index (BMI), and smoking were each identified as independent risk factors. Other studies have noted higher obesity rates in patients with idiopathic neuropathy, both with and without abnormal glucose metabolism. In addition, there is also evidence that

Metabolic Syndrome Features and Their Role in Diabetic Neuropathy

Glycemic control has long been the cornerstone of DSP therapy. However, large epidemiologic and treatment studies in patients with diabetes suggest obesity and dyslipidemia may be equally important risk factors. Hyperglycemia does not exist in isolation, and is one component of a broader metabolic syndrome with features initially identified due to their prediction for cardiovascular disease. Metabolic syndrome is defined as the presence of three of the following, increased fasting glucose, hypertriglyceridemia, decreased high-density lipoprotein-C (HDL-C), ethnicity-specific central obesity, and elevated blood pressure. Active drug treatment for any of these conditions in a given patient also meets criteria. Several metabolic syndrome features have been linked to neuropathy, particularly obesity and dyslipidemia, independent of hyperglycemia. The largest studies have examined metabolic syndrome contribution to neuropathy risk in patients with known diabetes. The EuroDiab study found DSP in 28% of type 1 diabetic patients. It was noted that many patients with good glucose control (hemoglobin A1c < 7%) had DSP, suggesting other risk factors were important. Among patients who did not have neuropathy at baseline, 23.5% developed neuropathy after an average follow up of 7.3 years. Hypertension, serum lipids and triglycerides, body mass index (BMI), and smoking were each identified as independent risk factors. Other studies have noted higher obesity rates in patients with idiopathic neuropathy, both with and without abnormal glucose metabolism. In addition, there is also evidence that
obesity is associated with abnormal autonomic function, early or subclinical autonomic neuropathy.\textsuperscript{17}

Hypertriglyceridemia is significantly more common in those with idiopathic neuropathy,\textsuperscript{18} and may be involved in its development and progression. Among 28,700 diabetic patients, serum triglyceride level was an independent stepwise risk factor for lower extremity amputation, often a consequence of neuropathy.\textsuperscript{19} In a cohort study of patients with mild to moderate diabetic neuropathy, elevated triglycerides significantly correlated with loss of sural nerve myelinated fiber density over the study duration (52 weeks), independently of disease duration, age, or diabetes control.\textsuperscript{13,18,20}

**Treatment of Hyperglycemia and Metabolic Syndrome**

Aggressive glycemic control has been shown in large, well-designed clinical trials to reduce the neuropathy risk in type 1 diabetes. The Diabetes Control and Complications Trial (DCCT) randomized 1441 patients with type 1 diabetes to intensive or standard glucose control. During the long-term follow-up, glycemic control was similar between patients initially randomized to the different treatment groups. Despite this fact, those who had 5 years of intensive control during the DCCT were less likely to have neuropathy 14 years later than those who had standard therapy (25% vs 35%, \(p < 0.001\)).\textsuperscript{21} Similar data supporting a benefit for aggressive glycemic control in type 2 diabetes are lacking. The ACCORD study, which randomized 10,251 early diabetic subjects (HgbA1c of > 7.4%) to either intensive (HgbA1c goal of 6.5%) or standard (goal 7.0–7.9%) therapy found no reduction in the risk of incident clinical neuropathy.\textsuperscript{22} A recent Cochrane Review of this topic concludes that aggressive glycemic control does not reduce clinical neuropathy risk.\textsuperscript{23}

The Steno-2 trial provides the best data on potential neuroprotective effects of metabolic syndrome control in patients with diabetes. Patients with type 2 diabetes were randomized to receive standard treatment or aggressive multimodal therapy to normalize weight, hypertension and lipid abnormalities, together with smoking cessation. Those in the multifactorial treatment arm were significantly less likely to develop coronary, cerebral, or peripheral vascular occlusive disease, but also nephropathy, retinopathy, and autonomic neuropathy.\textsuperscript{24} Somatic neuropathy and associated pain were not evaluated.

An evolving literature supports a role for exercise in neuropathy prevention and therapy. One prospective study compared neuropathy incidence in 78 type 2 diabetes patients randomized to supervised treadmill walking 4 hours weekly or bland counseling.\textsuperscript{25} HgbA1c did not improve significantly for either cohort, but exercise subjects improved fitness doubled VO\textsubscript{2} max and reduced waist circumference. Clinical neuropathy developed in 30% of nonexercisers compared with 7% of exercisers (\(p < 0.05\)). A smaller unrandomized study in subjects with DSP found 10 weeks of supervised exercise significantly improved reported neuropathic pain, as well as cutaneous axon sprouting.\textsuperscript{26} These results suggest that exercise may impact neuropathy through a mechanism other than improvement in glucose control.

Generally, however, once DSP is established, it has proved remarkably resistant to treatment. No human clinical trial has demonstrated reversal or improvement of DSP even with complete resolution of diabetes. Patients with type 1 diabetes who underwent pancreatic transplant were compared with matched subjects who received best medical therapy. Compared with medical therapy subjects, who experienced unremitting decline in clinical measures of peripheral nerve function, transplant recipients showed a stabilization of neuropathy progression, but minimal improvement over many years.\textsuperscript{27} With neuropathy progression, reversible metabolic factors tend to be supplanted by irreversible structural injury.\textsuperscript{28} Even in rodent models, spontaneous reversion to normoglycemia does not result in significant improvement of chronic diabetic neuropathy.\textsuperscript{29} These observations suggest future therapeutic efforts should focus on very early disease or even neuropathy prevention.

**Treatment Based on Recognized Steps in Diabetic Pathophysiology**

The pathophysiology of DSP is complex and several important mechanistic pathways have been identified. Neuropathy likely results as a combination of direct axonal injury due to metabolic consequences of hyperglycemia, insulin resistance, and toxic adiposity in addition to endothelial injury and microvascular dysfunction leading to nerve ischemia. Diabetest causes functional deficits in nitric-oxide-mediated microvascular reactivity as well as a structural microangiopathy that share pathologic features with microvascular injury to the retina. Additional relevant metabolic pathways include oxidative and nitrosative stress,\textsuperscript{30,31} accumulation of advanced glycation end products,\textsuperscript{32} direct toxic effects of free fatty acids and proinflammatory adipokines.\textsuperscript{33} These pathways produce microischemia of nutrient nerve arterioles, dysregulate axonal mitochondrial function, inhibit axonal transport of proteins necessary for distal axonal function, and elicit an autoimmune response.\textsuperscript{32}

Pathogenic elucidation spawned a plethora of animal models and medications designed to block specific putative pathogenic pathways. Despite several promising therapies in cell culture and animal models of diabetic neuropathy, no rational treatment has clearly proven effective at reversing or slowing progression. Multiple trials of small vessel vasodilatory agents showed no clinical response,\textsuperscript{34} nor did a large trial of nerve growth factor (NGF).\textsuperscript{35} Trials of aldose reductase inhibitors (ARI), which control entry of excess glucose into the polyol pathway and reduce glucose mediated oxidative stress and microvascular disease in animals, have generally shown no efficacy in humans.\textsuperscript{36,37}

Three related potential medications for DSP combine neuropathic pain relief with possible direct effect on neuropathic injury. Alpha lipoic acid, acetyl-L carnitine, and benfotiamine each act to reduce oxidative stress, which has been identified as a key component of neuropathy pathogenesis. In diabetes, excess lipids and glucose both produce oxidative
free radicals that directly damage axonal mitochondria and divert nitric oxide from its normal vasodilatory role, resulting in impaired vasoregulation and ischemia of nutritive arterioles.\textsuperscript{38} Alpha lipoic acid (ALA) is an orally bioavailable antioxidant. The Symptomatic Diabetic Neuropathy (SYDNEY) Study randomized diabetic neuropathy subjects to double-blinded treatment with either placebo or up to 1800 mg of oral ALA. Over the 5-week treatment course, subjects treated with any of the ALA doses reported a significantly greater reduction in neuropathic pain than did the placebo-treated controls.\textsuperscript{39} Most clinical measures of neuropathy severity did not significantly improve; previous studies had reported modest improvement in neuropathy measures following IV ALA injection.\textsuperscript{40} Alpha lipoic acid is regulated as a drug in many European nations, but is available in the United States as a dietary supplement. ALA may be started at a dose of 300 mg by mouth daily and titrated as high as 600 mg twice daily. ALA may lower blood glucose and thiamine stores, and has unpredictable effects on thyroid function.

Diabetes is associated with reduced serum levels and cellular concentrations of acetyl-L carnitine (ALC), another antioxidant that has been shown to inhibit lipid peroxidation and increase nitric oxide synthase and nitric oxide in experimental models. Two parallel randomized, blinded controlled trials used measures including the Visual Analog Pain Scale (VAS), and morphometric analysis of sural nerves to assess neuropathy severity at baseline and after 52 weeks of treatment; 1257 diabetic neuropathy subjects received either placebo or one of two ALC doses.\textsuperscript{41} ALC significantly improved sural morphology and VAS. These also improved significantly with the larger ALC dose. ALC is available as a nutritional supplement, often in combination with ALA, and a target dose of 500 mg daily is best supported.

Benfotamine or S-benzoylthiamine O-monophosphate is a vitamin B1 derivative with antioxidant properties. A Phase III study randomized 165 diabetic neuropathy subjects to either placebo or benfotamine.\textsuperscript{42} Subjects receiving active drug showed significant improvement in the neuropathy-specific Total Symptom Score and its pain subscore over the 6-week trial, with greater benefit in the 600 mg dose group. Taken together, trials of these medications strongly implicate oxidative stress as a contributor to neuropathy pathogenesis.

Delivery of a putative therapeutic agent to the target organ (dorsal root ganglia or nerve) without limiting off-target side effects has proven challenging. This issue was particularly problematic in the phase III NGF trial, in which even a low dose of NGF was complicated by symptomatic hyperalgesia.\textsuperscript{43} One solution to this problem is use of delivery vectors derived from the herpes simplex virus, which has tropism for dorsal root ganglia neurons. A recent phase I study of a replication deficient HSV vector expressing the gene for preproenkephalin in patients with cancer-related pain demonstrated an apparent dose-related treatment effect.\textsuperscript{44} Other studies have used plasmids (naked DNA) containing growth factor genes to deliver therapy to nerve via intramuscular injection. A small trial of a plasmid containing the gene for vascular endothelial growth factor suggested benefit, and other trials using this delivery system are underway.\textsuperscript{45}

Numerous physical, surgical, or energy therapies are purported to improve neuropathy by increasing vascular or microvascular blood flow. These include “triple decompressive surgery” to release the peroneal nerve at the fibular head and foot dorsum, and the tibial nerve at anatomic tunnels in the foot,\textsuperscript{46} fixed or pulsed magnetic field therapy,\textsuperscript{47,48} near infrared phototherapy,\textsuperscript{49} and various nonpenetrating laser therapies. In all cases, either rigorous blinded and randomized trials have not been performed, or as in the case of magnetic field therapy, these studies have not demonstrated improvement in nerve function.\textsuperscript{50}

### Treatment of Neuropathic Pain

A majority of DSP patients complain of neuropathic pain, making diabetes the single most common cause of neuropathy and neuropathic pain in industrialized countries. A cross-sectional study comparing 350 people with diabetes to 344 age- and sex-matched controls in Liverpool found chronic painful neuropathy in 16% of diabetic patients, but only 4% of controls. Evaluation of the same cohorts 5 years later found neuropathic pain continued for 77% of diabetic subjects, without significant improvement as measured by the Visual Analog Pain Scale despite multimodal pain treatment.\textsuperscript{51} One-third had not received specific treatment despite requesting pain medication from their physician. This result mirrors the frustrating experience of many patients and physicians in treating established neuropathic pain in DSP.\textsuperscript{52} A wide variety of antidepressants, antiepileptic drugs, opiates, and mixed serotonin/norepinephrine reuptake inhibitors have been shown to significantly reduce neuropathic pain compared with placebo in randomized controlled trials,\textsuperscript{52} but pain relief is incomplete for most patients.

**Tricyclic antidepressants** (amitriptyline, nortriptyline, desipramine) have been mainstays of neuropathic pain treatment, with efficacy proven in several well-designed studies.\textsuperscript{53} Tricyclic antidepressants are inexpensive, and because of their long half-life, dosing is simple. When administered 2 hours before bedtime, amitriptyline often aids in sleep initiation, even at low dose. This sedative effect is durable, and is of significant benefit for patients who report that neuropathic pain increases with rest, and makes it hard to fall asleep at night. A typical dose of amitriptyline is 50–200 mg, 2 hours before bedtime. To minimize side effects, patients should gradually increase their dose, beginning at 10 mg, and increasing by 10 mg increments every 5 days to an initial plateau dose of 50 mg nightly. Dosing increases can then proceed in 25 mg increments. Because of the risk for partial or complete heart block, older patients should have an electrocardiogram in evaluation of conduction defects. Orthostatic hypotension, urinary hesitancy, fatigue, somnolence, and confusion are also common dose-related side effects. Patients taking monoamine oxidase inhibitors should not take tricyclics.

**Gabapentin** is structurally related to the pain-modulating neurotransmitter, g-aminobutyric acid (GABA), although it acts neither as a GABA agonist or antagonist. Its mechanism is thought to be related to binding to the a 2 delta subunit of
voltage gated Ca\(^{2+}\) channels. In several placebo controlled, randomized trials examining patients with painful neuropathies, gabapentin has been shown to significantly reduce neuropathic pain and improve sleep.\(^{54}\) In the largest clinical trials, doses in excess of 1800 mg divided three times daily were often necessary for optimal pain relief. Dose escalation of gabapentin should begin at 300 mg taken 2 hours before bedtime, increasing in 300 mg increments every 3 to 7 days to 600 mg three times daily. This conservative escalation schedule minimizes side effects. A therapeutic trial should involve at least 4 weeks at a therapeutic dose, with some patients requiring 4800 mg daily in divided doses. Gabapentin is generally well tolerated, and renal excretion means there is no interaction with medications that undergo hepatic cytochrome p450 metabolism. Dizziness and somnolence are the only side effects reported to occur more frequently in patients taking gabapentin than in those receiving placebo.

**Pregabalin** (Lyrica\(^{65}\), Pfizer Pharmaceuticals, New York, NY) is structurally similar to gabapentin and offers a very similar pharmacokinetic, metabolic, and side-effect profile, with a somewhat faster onset of pain reduction. Pregabalin has been approved by the Food and Drug Administration (FDA) for treatment of neuropathic pain in diabetes, and for treatment of fibromyalgia.\(^{55}\) Dose escalation of pregabalin can begin at 75 mg twice daily, and increase by 75 mg increments to 150 mg twice daily.

**Duloxetine** is a selective serotonin and norepinephrine reuptake inhibitor FDA-indicated for neuropathic pain associated with diabetic DSP, as well as for depression, anxiety, pain associated with fibromyalgia, and chronic musculoskeletal pain. In two randomized controlled trials, diabetic subjects with painful DSP of less than 6 months duration showed statistically better cumulative pain relief over the 12-week trial period when administered duloxetine 60 mg daily compared with placebo.\(^{56}\) This is the recommended dose. Common side effects include nausea, somnolence, dry mouth, and constipation. Appetite suppression is common, but is often regarded as a benefit of the drug.

Gabapentin, pregabalin, and duloxetine are frequently offered in sequence to neuropathic pain patients, but have not been compared head-to-head in blinded or crossover trials. An open label trial in DSP patients who did not improve with gabapentin found no significant difference in efficacy between pregabalin and duloxetine.\(^{57}\) Retrospective review suggested a statistical advantage for pain relief to pregabalin (33% responders) compared with duloxetine (21%).\(^{58}\) Overall, none of these medications provides effective neuropathic pain control for the majority of DSP patients, and combination therapy has not been well evaluated.

**Opiates** have a defined role as adjunct treatment in poorly controlled neuropathic pain, but are often overlooked because of concerns for tolerance and addiction.\(^{59}\) The oral opiate oxycodone improved pain and quality of life in a small diabetic neuropathy cohort,\(^{60}\) and a larger study (338 subjects) found significantly enhanced pain relief when added in a randomized and double-blinded fashion to optimized gabapentin dosing.\(^{61}\) However, in a recent study of 62 diabetic neuropathy subjects, randomized addition of low-dose oxycodone did not significantly improve the neuropathic pain effects of pregabalin.\(^{62}\) The novel mu-opioid receptor binding agent tapentadol has recently been shown superior to placebo in reducing neuropathic pain in a randomized trial cohort of 395 subjects with diabetic neuropathy.\(^{63}\)

In practice, a short-acting agent, such as hydrocodone or oxycodone, can be used to slowly titrate the dose to efficacy. Once an effective dose has been found, conversion to a long-acting (“time contingent”) opiate such as extended release morphine (MS Contin) or oxycodone helps provide sustained pain relief with fewer side effects. A short-acting agent may be used for breakthrough pain or exacerbations. Ethanol and benzodiazepines synergize with opiates to cause respiratory depression and sedation. Patients should be counseled to avoid alcohol consumption. Constipation is the most common side effect of low-dose oral opiate use. Prophylactic institution of a bowel control regimen helps prevent constipation. Sedation and central respiratory depression are of concern at higher doses, and may be more dangerous in obese patients with obstructive sleep apnea.

Treating physicians are often reluctant to prescribe opiates due to concern for risk of addiction. Although physical dependence occurs in many patients, it is rarely a problem. A prospective study in patients with diabetes suggests that psychological dependence and addiction are rare when these agents are used for pain, even for long periods.\(^{64}\) Patients should taper off of opiates rather than stopping them suddenly. Patients at higher risk of addiction, such as those with a history of drug or alcohol abuse, may require referral to a pain specialist.

**Tramadol**, an agent that binds to opiate receptors and blocks reuptake of serotonin and norepinephrine, was significantly more effective than placebo in treating neuropathic pain in a 42-day double-blind placebo controlled study of 131 diabetic subjects,\(^{65}\) and in combination with acetaminophen was shown to be significantly more effective than placebo alone in a cohort of 160 subjects.\(^{66}\) Long-term use of Tramadol in patients with diabetic neuropathy did not result in significant tolerance or dose escalation.\(^{64}\)

**Mexiteline** is an orally active local anesthetic agent that showed statistically significant reduction in Visual Analog Pain Scale pain ratings for diabetic neuropathy patients in two small trials at doses of 225–675 mg day. Nausea and other gastrointestinal complaints were the most common side effects.\(^{57}\)

**Capsaicin cream** is applied topically, and acts to reduce pain sensation by depleting substance P from proximal terminals of cutaneous nociceptive c-fibers. Its use is well validated in patients with herpes zoster. In a study of 13 patients with painful diabetic neuropathy, capsaicin reduced Visual Analog Pain Scale ratings while improving heat pain perception threshold.\(^{68}\) Capsaicin is practical only for patients with small areas of neuropathic pain. Pragmatically, few patients tolerate capsaicin therapy: the cream must be applied three to four times daily using rubber gloves to avoid affecting nonpainful skin or mucosa. Failure to maintain treatment for even one dose allows substance-P regeneration and recrudescence of pain.
Several other anticonvulsants and antidepressants have been studied with mixed results. There are also several innovative and promising pain therapies in development (including the gene therapy approaches described above). The interested reader is referred to the review of neuropathic pain in this issue of *Seminars in Neurology*.

**Prevention of Neuropathy Complications: Falls and Ulcers**

Patients with peripheral neuropathy are at higher risk of falling, and this problem may be particularly acute in diabetics. Among 60 diabetic patients over the age of 55 years old, over one-third had fallen in the prior year. Neuropathy, sensory loss, and distal weakness were major risk factors.69 Bedside gait examination may be a relatively insensitive predictor of fall risk. Patients with neuropathy often fall when walking on uneven or irregular surfaces, and formal gait evaluation should include these testing conditions.70 Any DSP patient, or patients with poor lower extremity strength or vibration perception should be counseled regarding fall risk and consideration given to possible gait evaluation and physical therapy intervention.

Foot ulceration and consequent digit, foot, or limb amputation remains a common diabetic complication. Among 248 diabetic patients followed prospectively in tertiary care podiatric clinic, foot ulcers developed in 29% of subjects and 19% of feet over a mean 30-month follow-up.71 DSP increases the risk of ulceration sevenfold and contributes to over 60% of lower extremity amputations in diabetic patients.72 The increased risk is due to a combination of lack of protective sensation, abnormalities in blood flow that are often compounded by peripheral artery disease, abnormal sweating, and poor wound healing.73 Ulceration and amputation risk is also related to duration of neuropathy and severity of hyperglycemia. Daily self-examination, with a foot mirror if necessary; podiatric consultation and maintenance for toenails and bunions; orthotic foot support, and use of protective, wide-based shoes with adequate toe box and ankle support are recommended for patients at risk for ulcers. If stasis ulcers develop, nonsurgical debridement, application of hydrogels, and empiric antibiotic coverage for wound flora are appropriate therapy.74

**Summary**

In summary, effective management of hyperglycemia, symptom control, and prevention of ulcers and infection through screening and surveillance remain mainstays of diabetic neuropathy management four decades after their introduction. Rational therapies based on evolving understanding of diabetic neuropathy pathogenesis have been largely unsuccessful in humans. This failure may reflect, in part, the advanced neuropathy present in subjects of previous human trials. More sensitive and quantitative measures of early peripheral nerve injury, including skin biopsy for intraepidermal nerve fiber density, and confocal corneal microscopy, hold promise to identify neuropathy patients early in their disease course, when rational treatments may be more effective. At the same time, traditional and rational diabetic neuropathy treatments will be supplemented by novel cell-based therapy and targeted drug delivery systems.

**References**

202 The Diabetic Neuropathies: Practical and Rational Therapy

Singleton, Smith


neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008;8:33